PHARMA AND VENTURE CAPITAL ALLIANCES ARE ON THE INCREASE. GSK has partnered with Avalon Ventures in a 495 M USD deal, in a trend that J&J and Sanofi are also creating. The GSK deal is on top of having their own SR ONE VC fund who is collaborating with Sanderling Ventures (who partner also with J&J and Index Ventures). Sanofi has a collaboration with Third Rock Ventures. This is a welcome trend and shows that Big Pharma is reinventing its R&D model to be less NIH.
http://lnkd.in/JR69EC
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022